Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2019
At a glance
- Drugs Recombinant lactoferrin (Primary)
- Indications Inflammation
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2016 Status changed from recruiting to completed.
- 04 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.